Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Trueman, D. [1 ]
Ndirangu, K. [2 ]
Paine, A. [1 ]
Pilkington, H. [1 ]
机构：
[1] Source Hlth Econ, Hlth Econ & Stat, London, England
[2] Eisai Inc, Global Value & Access, Nutley, NJ USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1007P
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 50 条
  • [41] Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT
    Baron, Ari David
    Lopez, Carlos Lopez
    Chang, Stephen Lam
    Piscaglia, Fabio
    Ramji, Zahra
    Ren, Min
    Estenson, Kasey
    Vogel, Arndt
    Gholam, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials
    Pollock, Richard F.
    Brennan, Victoria K.
    Shergill, Suki
    Colaone, Fabien
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 341 - 349
  • [43] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
    Chen, Qiuping
    Sun, Quan
    Zhang, Jing
    Li, Baixue
    Feng, Quansheng
    Liu, Jibin
    PLOS ONE, 2024, 19 (03):
  • [44] Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE)
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Kim, Hyung-Don
    Ryu, Min-Hee
    Kang, Beodeul
    Chon, Hong Jae
    Hong, Jung Yong
    Lim, Ho Yeong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
    Yau, T.
    Galle, P. R.
    Decaens, T.
    Sangro, B.
    Qin, S.
    Park, J-W.
    Ikeda, M.
    Tai, D. W. M.
    Chiu, C-F.
    Chon, H. J.
    Kang, Y-K.
    Hiraoka, A.
    Huang, Y-H.
    Lee, T-Y.
    Numata, K.
    Yamashita, T.
    Ogata, T.
    Hreiki, J.
    Lu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1450 - S1451
  • [46] Efficacy and safety evaluation of first-line systemic treatments for unresectable esophageal squamous cell carcinoma: a network meta-analysis
    Shi, Huiling
    Tan, Yong
    Ma, Chao
    Wei, Yushan
    Shi, Fengling
    Wang, Juan
    Xu, Caihua
    Liang, Rongrui
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] Pembrolizumab plus lenvatinib (P plus L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
    Yan, Kevin
    Rane, Pratik
    Schmidinger, Manuela
    Peer, Avivit
    Druyts, Eric
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 422 - 422
  • [48] Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Lencioni, Riccardo
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Cheng, Ann-Lii
    Piscaglia, Fabio
    Han, Guohong
    Ikeda, Masafumi
    Simon, Krzysztof
    Komov, Dmitry
    OuYang, Xuenong
    Evans, T. R. Jeffry
    Sung, Max W.
    Binder, Terri A.
    Damon, Andrew
    Kraljevic, Silvija
    Ren, Min
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
    Kim, Beom Kyung
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kang, Beodeul
    Ha, Yeonjung
    Kim, Do Young
    Hwang, Seong Gyu
    Chon, Young Eun
    Chon, Hong Jae
    CANCERS, 2022, 14 (07)
  • [50] A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
    Sharma, A.
    Singh, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S616 - S617
12345